Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Copper histidine subcutaneous - Cyprium Therapeutics

Drug Profile

Copper histidine subcutaneous - Cyprium Therapeutics

Alternative Names: Copper histidinate; CUTX 101

Latest Information Update: 10 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Child Health and Human Development
  • Developer Cyprium Therapeutics; National Institute of Child Health and Human Development
  • Class Heavy metals; Imidazoles; Small molecules
  • Mechanism of Action Heavy metal replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Menkes kinky hair syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Menkes kinky hair syndrome

Most Recent Events

  • 30 Aug 2019 Clinical trials (Expanded Access programme) in Menkes kinky hair syndrome (In children) in USA (SC) (NCT04074512)
  • 05 Oct 2018 Chemical structure information added
  • 12 Sep 2018 Pharmacodynamics data from preclinical trials in released by Fortress Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top